Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - Nomura

UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS

November 11, 2015 9:44 AM EST

(Updated - November 11, 2015 9:49 AM EST)

(correction: price target is $255)

UBS analyst Marc Goodman reiterated a Buy rating and $255 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's business update. The analyst said eventually fundamentals will matter again. Goodman listed 6 takeaways from... More

JPMorgan Cuts PT on Valeant (VRX) to $225

November 11, 2015 6:42 AM EST

JPMorgan trims its price target on Valeant Pharma (NYSE: VRX) from $265 down to $225. The firm maintained its Overweight rating on Valeant

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

... More

Philidor Rx Disappointed Relationship with Valeant (VRX) Has Ended

November 10, 2015 5:22 PM EST

Philidor Rx said in a statement:

We have valued our close working relationship with Valeant (NYSE: VRX) and are deeply disappointed that is has come to an end. It is unfortunate that this outcome was influenced by market forces, media misperceptions, and inflammatory,... More

Valeant Pharma (VRX) Moves Solidly Into the Green, Erasing 7.5% Loss

November 10, 2015 2:01 PM EST

Embattled Valeant Pharma (NYSE: VRX) has gone solidly positive territory mid-day after trading down as much as 7.5% earlier. Shares last traded at $85.63, up 0.3%. Upside is related to... More

Citron's Left Says Valeant Pharma (VRX) Short 'Significantly Scaled-Down' from Initial Position

November 10, 2015 12:33 PM EST

Citron's Andrew Left says short in Valeant Pharma (NYSE: VRX) is "significantly scaled down" from where it initially was.

... More

Mallinckrodt (MNK) is not Valeant Pharma (VRX) 'it's worse' - Left

November 10, 2015 12:27 PM EST

Mallinckrodt (NYSE: MNK) is not Valeant Pharma (NYSE: VRX), "it's worse", Citron Research's Andrew Left says

... More

Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'

November 10, 2015 9:25 AM EST

With its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.

CEO Michael Pearson also the company "is going to survive" and... More

Drugmaker Valeant to feel sting of closing controversial pharmacy

November 10, 2015 8:26 AM EST

By Euan Rocha and Rod Nickel

TORONTO/WINNIPEG (Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said on Tuesday its dermatology business would be hurt in the short term as it moves rapidly to sever ties with a controversial specialty pharmacy.

As of last week, Philidor Rx Services has stopped handling insurance claims for drugs and it will cease operations by the end of January, Valeant Chief Executive Officer Mike Pearson told investors and analysts on a conference call on Tuesday.

The call, however,... More